China

Acepodia Plays Dual-Payload Ace To Join Global ADC Race

 

Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.

Chinese Firms Expand Solo Global Phase III Activity Including US Sites

 

Throughout 2024, Chinese firms as sole sponsors initiated a total of seven global Phase III trials that including US sites. BeiGene, Genfleet and InnoCare are expected to add four similar studies this year.

Another Major DLL3 ADC Alliance As Hengrui Links With IDEAYA

 

The new year has already brought multiple deals for China-originated antibody-drug conjugates in the DLL3 class, which companies in the country dominate.

CARsgen Claims First Clinical Win For CLDN 18.2 CAR-T In G/GEJ Adenocarcinoma

 

CARsgen's anti-Claudin 18.2 CAR-T therapy satricabtagene autoleucel has met its endpoint in a pivotal Phase II trial in later-stage gastric/gastroesophageal junction adenocarcinoma, paving the way for a China NDA filing.


TCE Specialist CytoCares Makes Inroads Into Autoimmune Space

 

CytoCares’ CEO shares plans for CC312, a potentially first-in-class trispecific antibody for autoimmune disorders it sees as differentiated from global rivals.

Few Blockbusters So Far From China’s First-In-Class Innovation

 

Some five years on from the first approval of a novel drug originated in China, 10 first-in-class drugs of Chinese origin have been commercialized. But the results have been mixed, with few actual or potential blockbusters.

Chinese Biotechs Edge Close To Bigger VC/PE Deals In November

 

In addition to C-Ray Therapeutics’ $100m-plus series A+ round, Allink Biotherapeutics and IMPACT Therapeutics closed VC/PE-backed financing deals worth $42m and $34m, respectively. Other Chinese biotechs also sealed smaller deals.

Simcere’s Sublingual Edaravone Nears International Phase III Trial After China Approval

 

China’s fresh approval of a sublingual form of Simcere's edaravone/dexborneol brain cytoprotective agent for acute ischemic stroke is paving the way for an international Phase III study in this indication.


Vabysmo Hopes To Ride New Coverage In China, Data To Expand In Asia

 

Roche's blockbuster ophthalmic drug set for China reimbursement list inclusion in three indications and shows positive interim results in PCV.

Hua’s China Deal With Bayer For Novel Oral Diabetes Drug Collapses

 

Hua Medicine’s HuaTangNing (dorzagliatin), the world’s first approved glucokinase activator, has apparently fallen short of restoring Bayer to its pre-2020 frontrunner position in China’s market for oral type 2 diabetes drugs, and the two companies' alliance is now set to be dissolved.

Looking Beyond BioNTech/Biotheus To Future Potential China Deals

 
• By 

BioNTech and Biotheus’s recent acquisition deal and the current tough funding environment for Chinese biotechs may point to further potential transactions at attractive valuations. Bispecific antibodies and ADCs in oncology are possible targets for cross-border deals.

Trump 2.0: India Pharma On A Good Wicket?

 

US President-elect Donald Trump’s second term is seen in general as “bad news” for Asia, especially China, by some analysts. But the outlook for India pharma appears upbeat, says a cross-section of experts.


Fosun Pharma’s Global R&D Head On Original Innovation In China

 

Original innovation in drug development is vital for Chinese pharmas to grow into international majors within a decade, while originality is not necessarily restricted to the first-in-class category, Xingli Wang, head of Fosun Pharma’s Global R&D, shares his thoughts with Scrip.

China Race On For New Wave Of Novel Drugs

 

A new drug-hunting initiative funded by the Chinese government will focus on novel therapies for chronic diseases and encourage academia-industry collaboration.

HopeMed Hopes For First-Line Inroads In Endometriosis-Associated Pain

 

Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.

Sponsored by:

Precision Oncology Drug Development in China: Opportunities, Challenges, and Fast Paths Forward

Learn more about how China’s biopharmas are going global by working with dependable and trustworthy companion diagnostics partners.


As China Biotechs Mull Global Approaches, Commercial Insurance Holds Key To Domestic Success

 
• By 

Low prices and intense competition for innovative drugs at home continue to drive Chinese biotechs' globalization. Broader domestic commercial health insurance might provide the key to change.

China Biotechs Hang Onto Smaller VC/PE Funding Deals In September, October

 

LaNova Medicines, as well as other Chinese RNA interference specialists and developers of stem cell-based therapies, were among those securing new funds from venture capital and private equity firms over the past few months.

AZ China President Under Investigation By Chinese Authorities

 

The exact causes leading to Chinese authorities’ investigation of the UK major remain unclear at this point, but its key oncology drugs are facing fierce local competition from homegrown rivals.

China Innovation, Large Market Continue To Lure Foreign Investment

 
• By 

High patient needs, a large healthcare market and innovation potential in the biotech sector in China still appear to be maintaining and attracting investments by overseas biopharma companies, including by Bayer and Lilly in biotech start-ups and Lilly in manufacturing.